Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  fludeoxyglucose F 18
Find trials that include:  Any drugs shown
Results 1-25 of 47 for your search:
Start Over
A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 30 and over
Trial IDs: DEK-DKK1-P101, NCI-2014-00197, DKN-01, LY2812176, NCT01711671
18F FPPRGD2 Positron Emission Tomography/Computed Tomography in Predicting Early Response in Patients with Cancer Receiving Anti-Angiogenesis Therapy
Phase: Phase II, Phase I
Type: Diagnostic
Age: 18 and over
Trial IDs: VARIMG0002, NCI-2013-00535, NCT01806675
Fludeoxyglucose F 18-PET/CT Imaging in Assessing the Tumor and Planning Neck Surgery in Patients With Newly Diagnosed Head and Neck Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Diagnostic, Health services research
Age: 18 and over
Trial IDs: ACRIN 6685, NCI-2011-01972, CA80098, CDR0000654703, NCT00983697
Response-Based Therapy Assessed by PET Scan in Treating Patients with Stage I or Stage II Hodgkin Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Age: 18 to 60
Trial IDs: CALGB 50801, NCI-2011-02034, CDR0000669076, NCT01118026
Zoledronic Acid in Treating Patients With Advanced Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: UAB0901, NCI-2011-03129, NCT01204203
Ofatumumab and Bendamustine Hydrochloride with or without Bortezomib in Treating Patients with Untreated Follicular Non-Hodgkin Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CALGB 50904, NCI-2011-02625, CDR0000694298, NCT01286272
PET-Directed Therapy in Treating Patients with Limited-Stage Diffuse Large B-Cell Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1001, NCI-2011-02673, CDR0000700624, SWOG-S1001, NCT01359592
Cabozantinib in Treating Patients with Hormone Receptor-Positive Metastatic Breast Cancer with Bone Involvement
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-208, NCI-2011-03519, NCT01441947
Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients with Previously Untreated Stage II-IV Hodgkin Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 60 and over
Trial IDs: NU 11H01, NCI-2011-00684, NCT01476410
Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients with Stage III Non-small Cell Lung Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RTOG 1106/ACRIN 6697, NCI-2012-00107, CDR0000721619, RTOG-1106, NCT01507428
Axitinib in Treating Patients with Melanoma That is Metastatic or Cannot Be Removed by Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 197811, NCI-2011-03037, NCT01533948
Ziv-Aflibercept and Combination Chemotherapy in Treating Patients with Previously Untreated Colorectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU 11182, NCI-2012-01167, 2012C0055, NCT01652196
Cabozantinib-S-Malate in Treating Patients with Metastatic Bladder Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 12-C-0205, NCI-2013-01555, 120205, 12-C-0205J, P11900, 9236, NCT01688999
Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 16 and over
Trial IDs: 12-000153, NCI-2012-01548, NCT01697527
FDG-PET in Predicting Treatment Response in Patients with Newly Diagnosed Stage II-IV Breast Cancer Receiving Pertuzumab and Trastuzumab Prior to Surgery
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: TBCRC 026, NCI-2014-01543, NA_00080994, NA_00080994 / CIR00002510, NCI-2014-00245, NCT01937117
Total Marrow and Lymphoid Irradiation and Chemotherapy before Donor Stem Cell Transplant in Treating Patients with High-Risk Acute Lymphocytic or Myelogenous Leukemia
Phase: Phase II
Type: Treatment
Age: 18 to 60
Trial IDs: 14012, NCI-2014-00639, 105023, 108097, 112566, NCT02094794
Intensity-Modulated Image-Guided Adaptive Radiation Therapy and Cisplatin in Treating Patients with Locally Advanced Head and Neck Squamous Cell Cancer
Phase: Phase I
Type: Treatment
Age: 19 and over
Trial IDs: MCC 13222, NCI-2010-02340, HM13222, NCI-2011-00846, NCT01283178
Stereotactic Radiation Therapy in Treating Patients With Liver Metastases
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: UPCI 09-051, NCI-2013-00407, NCT01360606
Sirolimus and Vismodegib in Treatment of Patients with Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed by Surgery
Phase: Phase I
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Age: 18 and over
Trial IDs: MC1111, NCI-2011-03809, NCT01537107
Ipilimumab in Treating Patients with Relapsed Hematologic Malignancies after Donor Stem Cell Transplant
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-537, NCI-2013-00739, 9204, NCT01822509
Propranolol Hydrochloride in Reducing FDG Uptake in Brown Fat Tissue on PET Imaging in Younger Patients with Cancer
Phase: Phase I
Type: Diagnostic, Health services research
Age: 12 to 29
Trial IDs: PROPRANOLOL-PET, NCI-2014-01976, NCT02165683
18F-FDG PET/CT before Surgery in Mapping Lymph Nodes in Patients With Stage IB Cervical Cancer or High-Grade Endometrial Cancer
Phase: Phase I
Type: Diagnostic
Age: 18 to 75
Trial IDs: 14-222, NCI-2014-02552, NCT02285192
18F-FDG PET or 1H-MRSI in Assessing Tumor Activity in Younger Patients with Brain Tumors
Phase: No phase specified
Type: Diagnostic, Natural history/Epidemiology
Age: 1 to 21
Trial IDs: 03-C-0278, NCI-2013-02042, 030278, NCT00070512, NCI-03-C-0278, NCT00067821
Fluorine F 18 Sodium Fluoride and Fludeoxyglucose F 18 Combined Positron Emission Tomography/Computed Tomography Scan in Diagnosing Patients With Skeletal Neoplasms
Phase: No phase specified
Type: Diagnostic
Age: Over 18
Trial IDs: VAR0024, NCI-2011-00804, 9434, 98043, NCT00725387
Start Over